Neuroblastoma (NB) is a common pediatric tumor, which exhibits a wide range of clinical heterogeneity. NB can regress in some cases (favorable NB) or progress relentlessly in others despite the most intensive treatment (unfavorable NB). The goal of this study is to explore therapeutic strategies for unfavorable NB based on our understanding of """"""""Favorable NB Genes"""""""". Favorable NB genes are defined as genes whose high-level expression predicts good disease outcome of NB and forced expression of these genes in unfavorable NB results in growth suppression. Our recent studies have shown that inhibitors of DNA methylation, histone deacetylation and proteasomes reactivate favorable NB genes in unfavorable NB cells and suppress their growth in vitro and in vivo. Based on these observations, we hypothesize that chemotherapeutic agents that enhance the expression of favorable NB genes in unfavorable NB can convert these malignant tumors to the benign counterparts. To address this, (1) we will examine whether a specific histone deacetylase inhibitor, Trichostatin A (TSA) works independently or in combination with a potent proteasome inhibitor, YU101 and/or with a DNA methylation inhibitor, 5-aza-2'-deoxycitidine (5AdC), in enhancing favorable NB gene expression, inducing differentiation, and inhibiting growth and metastasis of unfavorable NB. (2) We will identify genes that provide NB with a favorable phenotype by performing gene expression profiling analyses on favorable vs. unfavorable NB and on TSA, YU101 or 5AdC-treated vs. control NB cells. We will examine the expression pattern of these favorable NB candidate genes in a cohort of NB to determine whether their high-level expression predicts favorable NB outcome. We will confirm their identity as favorable NB genes by examining their ability to suppress growth of NB cell lines in vitro and in vivo. We will determine whether the growth suppressive effect of favorable NB genes is due to inhibition of cell proliferation or acceleration of cell death. We will also examine whether the identified favorable NB genes induce differentiation and/or inhibit angiogenesis. Finally, based on their molecular characteristics, we will construct a functional relationship map among the favorable NB gene products. This map will serve as a blueprint for the development of an effective therapeutic strategy for unfavorable NB in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA097255-03
Application #
6947610
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Arya, Suresh
Project Start
2003-04-01
Project End
2008-03-31
Budget Start
2004-07-01
Budget End
2005-03-31
Support Year
3
Fiscal Year
2004
Total Cost
$251,451
Indirect Cost
Name
Emory University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Ikegaki, Naohiko; Hicks, Sakeenah L; Regan, Paul L et al. (2014) S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines. Int J Oncol 44:35-43
Ikegaki, Naohiko; Shimada, Hiroyuki; Fox, Autumn M et al. (2013) Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas. Proc Natl Acad Sci U S A 110:6097-102
Regan, Paul L; Jacobs, Joshua; Wang, Gerald et al. (2011) Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Int J Oncol 38:105-12
Torres, Jaime; Regan, Paul L; Edo, Robby et al. (2010) Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas. Int J Oncol 37:983-91
Kung, Bing; Zhao, Huaqing; Hicks, Sakeenah L et al. (2009) Biological significance of EPHA2 expression in neuroblastoma. Int J Oncol 35:845-50
Ikegaki, Naohiko; Gotoh, Takahiro; Kung, Bing et al. (2007) De novo identification of MIZ-1 (ZBTB17) encoding a MYC-interacting zinc-finger protein as a new favorable neuroblastoma gene. Clin Cancer Res 13:6001-9
Tang, Xao X; Zhao, Huaqing; Kung, Bing et al. (2006) The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res 66:2826-33
Tang, Xao X; Robinson, Marjorie E; Riceberg, Justin S et al. (2004) Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma. Clin Cancer Res 10:5837-44